These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35077038)

  • 1. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
    Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
    Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
    J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine.
    Maher DI; Hogarty D; Ben Artsi E
    Orbit; 2023 Dec; 42(6):630-634. PubMed ID: 35499172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.
    Sharif N; Opu RR; Saha T; Khan A; Aljohani A; Alsuwat MA; García CO; Vázquez AA; Alzahrani KJ; Miramontes-González JP; Dey SK
    Sci Rep; 2024 Oct; 14(1):23794. PubMed ID: 39394252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
    Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer.
    Cruz VA; Guimarães C; Rêgo J; Machado KLLL; Miyamoto ST; Burian APN; Dias LH; Pretti FZ; Batista DCFA; Mill JG; de Oliveira YGP; Gadelha CSE; da Penha Gomes Gouveia M; Moulin ACS; Souza BO; Aguiar LGR; Vieira GSS; Grillo LL; de Lima MD; Pasti LP; Surlo HF; Faé F; Moulaz IR; Macabú MO; Ribeiro PDC; Magalhães VO; de Aguiar MF; Biegelmeyer E; Peixoto FMMMC; Kayser C; de Souza AWS; de Moura Castro CH; Ribeiro SLE; Telles CMPF; Bühring J; de Lima RL; Dos Santos SHO; Dias SEB; de Melo NS; da Silva Sanches RH; Boechat AL; Sartori NS; Hax V; Dória LD; de Rezende RPV; Baptista KL; Fortes NRQ; de Melo AKG; Melo TS; de Abreu Vieira RMR; Vieira ASR; Kakehasi AM; Tavares ACFMG; de Landa AT; da Costa PVT; Azevedo VF; Martins-Filho OA; Peruhype-Magalhães V; de Medeiros Pinheiro M; Monticielo OA; Dos Reis-Neto ET; Ferreira GA; de Souza VA; Teixeira-Carvalho A; Xavier RM; Sato EI; Valim V; Pileggi GS; da Silva NA
    Adv Rheumatol; 2024 Aug; 64(1):58. PubMed ID: 39135131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Lymphocytic Vasculitis After Administration of the Second Dose of AZD1222 (Oxford-AstraZeneca) Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Casuality or Causality?
    Ungari M; Pezzarossa E
    Am J Dermatopathol; 2022 Jan; 44(1):80-82. PubMed ID: 34726187
    [No Abstract]   [Full Text] [Related]  

  • 16. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.
    Sprute R; Schumacher S; Pauls M; Pauls W; Cornely OA
    Drugs R D; 2021 Dec; 21(4):371-374. PubMed ID: 34351606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalized Edema and Pseudothrombocytopenia After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Report.
    Bokel J; Mendes-de-Almeida DP; Martins-Gonçalves R; Palhinha L; Vizzoni AG; Correa DF; Brandão LGP; Bozza PT; Grinsztejn B
    Front Public Health; 2022; 10():907652. PubMed ID: 35692333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
    Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
    J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2.
    Plüß M; Mese K; Kowallick JT; Schuster A; Tampe D; Tampe B
    Front Immunol; 2021; 12():784145. PubMed ID: 35116025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.